10 Strategic Considerations When Outsourcing Production of In Vitro Diagnostics
The choice of whether to outsource production of an in vitro diagnostic (IVD) or invest and develop inhouse capabilities is a foundational business decision. Capacity, capabilities and resources must all be assessed to determine the best course of action.
Considerations for Efficient Scale-Up of PSCs in Suspension Culture
Download this whitepaper to discover scale-up considerations such as suspension culture passaging strategies, medium exchange strategies plus suspension culture seeding density.
Aberrant Cytokine Activity in the Host Immune Response to COVID-19 Leads to Cytokine Release Syndrome
Since the first cases of COVID-19 were identified in December 2019, the disease has spread across the world, claiming over half a million lives and affecting millions of others.
Use of Laboratory Balances in the Pharmaceutical Industry
Download this whitepaper to learn more about balance requirements such as repeatability and minimum sample weight, equipment performance as well as use of internal test weights.
Phenotypic and Functional Characterization of CAR-T Cells
The successful use of immunotherapies to help combat cancer has expanded rapidly in the last few years, with many therapies now approved for clinical use.
Advances in the Stability and Delivery of mRNA Therapeutics
Download this whitepaper to learn more about mRNA therapeutics including how they could treat genetic diseases and cancer, the challenges associated with delivery and dosage as well as how to avoid an unwanted immune response.
Accelerating Cancer Immune Cell Therapies
As we have gained a greater understanding of cancer biology, therapeutic interventions have evolved from a one-size-fits-all approach to more targeted approaches, which afford patients not only longer lives but increased quality of life.
mRNA Vaccine Approvals for COVID-19
In this cell and gene therapy insights expert roundtable, a panel of four experts will answer some central questions surrounding the development of novel biotherapeutics.
Autologous CAR T-Cell Manufacturing
Cell-based chimeric antigen receptor (CAR) T-cell therapies have rapidly advanced from preclinical research. This success has driven an influx of companies to further develop CAR T-cell constructs to make them more effective, safe and persistent.
Challenging Host Cell Protein Assays for Improved Risk Mitigation
Host Cell Proteins (HCPs) are a heterogeneous, complex group of proteins that derived from the host cell. Regulatory agencies examine each protein drug on a case-by-case basis to determine appropriate maximum acceptable levels of HCPs considering patient risk.